CRISPR & Gene Editing Revolution – Upcoming Catalysts (XDNA ETF) – Kelly ETFs – 8.24.22

Overview:
Title: CRISPR & Gene Editing Revolution – Upcoming Catalysts (XDNA ETF)
Date: Wednesday, August 24, 2022
Time: 1:00 PM Eastern Daylight Time
Duration: 1 hour

Register Now:
Already Registered?
Accepted for one hour of CFP®, CFA® & CIMA®, CIMC®, CPWA® or RMA CE Credit for live webcast attendees. RIA Database is registered with the CFA Institute as a Sponsored Provider of Live CE Programs for CFA Charterholders. To receive credit, please enter your CFP Board Number/CIMA ID Number/CFA Institute ID below.
*I am a financial professional. I understand that this event is for financial professionals only, and I may be contacted by the sponsor.

Summary:

Now On Demand

CRISPR technology is at a 2007 iPhone moment where it is about to change healthcare as we know it. Learn about the upcoming catalysts for publicly traded gene editing companies and the recent developments, including the first patient receiving a gene-editing drug that treats heart disease by permanently lowering cholesterol.

CRISPR and Gene Editing has the potential to disrupt virtually every facet of our lives, from curing genetic diseases, detecting and treating cancers, treating HIV, to even bioengineering new crops and plants to feed the world’s growing population. At its core, CRISPR is a pair of biological scissors that cuts and replaces genes in living organisms’ cells. While the possibilities of CRISPR and gene editing are near limitless, we are truly just scratching the surface of what these innovative technologies can accomplish.

Participants will learn how the Kelly CRISPR & Gene Editing Technology ETF (Nasdaq: XDNA) is designed to capitalize on the next generation of healthcare by investing in CRISPR & Gene Editing companies disrupting the genomic and life science industries. XDNA seeks to invest in over 20 companies leading the CRISPR revolution – check out the Fund and Fact Sheet here.

Participants will learn:

  • What is CRISPR & Gene Editing Technology
  • 2nd Half Catalysts and developments in 2022
  • The Future of Gene Editing
  • The Publicly Traded Companies
  • The CRISPR & Gene Editing Sub-Sectors: CRISPR & Gene Editing Technology, Gene Editing Development Solutions, Gene Editing Sequencing Solutions
  • How to Implement the Kelly CRISPR & Gene Editing Technology ETF (Nasdaq: XDNA)

Speaker:
Kevin Kelly Kevin Kelly Founder, Chief Executive Officer Kelly Intelligence │ Kelly ETFs

At Kelly ETFs, Kevin is responsible for ETF product design, structuring, managing retail and institutional investment research, and capital markets. Kevin is the Founder and CEO of Kelly Intelligence, an investment management and intelligence firm that seeks to bring cutting-edge products, with forward-looking exposure. Its growing suite of indexes provide highly liquid, pure-play access to innovative business models, emerging industries, and disruptive technologies. He also serves as the CEO of Kelly Benchmark Indexes the index provider, and sponsor, of the SRVR and INDS real estate ETFs. In September 2014, Nasdaq named Kevin an ‘ETF Insider,’ and he is a recognized leader in ETF design, distribution and growth with his extensive track record of launching multi-billion dollar ETFs. Kevin’s thought leadership on markets, derivatives, e-commerce, and technology can be found weekly in top media outlets.
Limited Operating History Risk. The Fund is a recently organized investment company with a limited operating history. As a result, prospective investors have a limited track record or history on which to base their investment decision.

DNA Modification Technology Company Risk. DNA modification technology companies face intense competition, and products and services with a potentially short product life. These companies will generally require large amounts of capital expenditures on research and development, with no guarantee that the product or service would be successful. They may be heavily dependent on intellectual property rights. The laws related to these rights can vary and there is no guarantee that a company will be able to successfully protect their intellectual property rights. These companies, like other health care companies, are subject to various government and regulator oversight that could hamper or impede their operations.

Foreign Securities Risk. Investments in non-U.S. securities involve certain risks that may not be present with investments in U.S. securities. For example, investments in non-U.S. securities may be subject to risk of loss due to foreign currency fluctuations or to political or economic instability.

Investing involves risk including possible loss of principal.

Before investing carefully consider a funds investment objective, risks, charges, and expenses contained in the prospectus available at KELLY ETFs. Read carefully before investing.

Distributor: Foreside Fund Services, LLC.